ASX Share rice
Tue 04 Aug 2020 - 09:01:am (Sydney)

NOX Share Price

NOXOPHARM LIMITEDNOXPharmaceuticals, Biotechnology & Life Sciences

NOX Company Information

Name:

Noxopharm Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

828 Pacific Highway Gordon NSW Australia 2072

Phone:

61 2 9144 2223

Founder, Exec. Chairman & CEO:

Dr. Graham Edmund Kelly

Company Sec.:

Mr. David James Franks C.A., J.P., B.Ec, BEc, CA, F Fin, JP.

Chief Financial Officer:

Mr. Shawn Van Boheemen

Chief Scientific Officer:

Dr. John Wilkinson

Chief Medical Officer:

Dr. Gisela Mautner

Company Overview:

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors. Noxopharm Limited has a clinical alliance with GenesisCare for the combined therapy of Veyonda and 177Lu-PSMA. The company was incorporated in 2015 and is based in Gordon, Australia.

NOX Share Price Information

Shares Issued:

152.29M

Market Capitalisation:

$43.40M

Revenue (TTM):

$4.25M

Revenue Per Share (TTM):

$0.04

Earnings per Share:

$-0.092

Operating Margin (TTM):

$-3.22

Return On Assets (TTM):

$-1.16

Return On Equity (TTM):

$-39.41

Quarterly Revenue Growth (YOY):

0.153

Gross Profit(TTM):

$3.75M

Diluted Earnings Per Share (TTM):

$-0.119

NOX CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-3,201

Change To Liabilities:

$600.15K

Total Cashflow From Investing Activities:

$-3,201

Net Income:

$-11,222,787

Total Cash From Operating Activities:

$-9,775,765

Depreciation:

$62.10K

Change To Inventory:

$572.61K

Change To Account Receivables:

$-37,757

Capital Expenditures:

$6.40K

NOX Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-12,572,581

Net Income:

$-11,222,787

Gross Profit:

$3.75M

Operating Income:

$-15,680,340

Interest Expense:

$650.90K

Total Revenue:

$3.75M

Total Operating Expenses:

$15.68M

NOX Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$37K

Total Liabilities:

$5.75M

Total Stockholder Equity:

$-100,675

Total Assets:

$4.30M

Common Stock:

$28.70M

Other Current Assets:

$696.40K

Retained Earnings:

$-33,256,914

Other Assets:

$118.82K

Cash:

$2.91M

Total Current Liabilities:

$5.75M

Short-Term Debt:

$3.93M

Property - Plant & Equipment:

$256.84K

Net Tangible Assets:

$-137,675

Total Current Assets:

$3.89M

Net Receivables:

$160.40K

Short-Term Investments:

$412.65K

Inventory:

$696.40K

Accounts Payable:

$1.49M

Non Currrent Assets (Other):

$118.82K

Short-Term Investments:

$412.65

Non Current Liabilities Total:

$0

NOX Share Price History

NOX News

23 Jul, 2020
Noxopharm has claimed a breakthrough in the search for restoring immune function within "cold" microtumors, converting them to so-called "hot" tumors.
14 May, 2020
Investing in stocks comes with the risk that the share price will fall. Anyone who held Noxopharm Limited (ASX:NOX...
25 Feb, 2020
The FDA has approved Noxopharm's IND application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.
14 Feb, 2020
Noxopharm is pleased to announce positive interim results from its LuPIN Phase 1/2 clinical trial.
02 Dec, 2019
Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger.
06 Nov, 2019
Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth.
22 Oct, 2019
It hasn't been the best quarter for Noxopharm Limited (ASX:NOX) shareholders, since the share price has fallen 12% in...
18 Oct, 2019
Noxopharm (NOX.AX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM). GBM remains a poorly managed cancer, with surgery, radiotherapy and the chemotherapy drug, temozolomide, the current standard of care, offering median survival of only 12-15 months.
30 Sep, 2019
On further review of the interim data, Noxopharm now sees an important and exciting story emerging that it considers needs to be brought to market attention. Noxopharm is developing Veyonda® as a drug to boost the effectiveness of two forms of radiation therapy in prostate cancer with the aim of relieving pain, decreasing the activity of the cancer and extending life.  In one form, the radiation is delivered externally (DARRT study).
17 Sep, 2019
Noxopharm (NOX.AX) (‘Noxopharm’ or the ‘Company’) is pleased to announce that Australian clinicians will be presented updates on research relating to the use of Veyonda® (idronoxil) with radiotherapy for the treatment of prostate cancer at the Clinical Oncology Society of Australia (COSA) annual scientific meeting in November this year.  This is the key meeting for oncologists in Australia and this year there is a program focus on urological cancer. The Company is releasing details of the presentations now as the meeting organisers have released the scientific abstracts earlier than expected via the meeting website.
28 Aug, 2019
The Company’s DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda® to increase tumour response to low-dose radiotherapy in prostate cancer. The Company previously reported on the patients in the dose-escalation or first part of the study on 2 May 2019. Dr Greg van Wyk, Noxopharm CEO and Chief Medical Officer, said: ‘Today’s data builds positively on the previously released figures obtained from the first group of patients living with end-stage metastatic castration-resistant prostate cancer (mCRPC).
21 Aug, 2019
Noxopharm Limited (NOX.AX) (‘Noxopharm’ or the ‘Company’) is pleased to provide an update on results from a series of key proof-of-principle experiments in mice that are exploring the interaction between Veyonda® and radiotherapy in a novel and potentially transformative treatment regimen known as DARRT (Direct and Abscopal Response to Radiotherapy). An abscopal response is where radiation directed at a tumour in one part of the body leads to an anti-cancer response both in the irradiated tumour as well as in tumours elsewhere in the body.